Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Oncology Panel To Weigh Independent Review Of PFS Event Subset

Jun 04 2012

• By Sue Sutter

Related Content

Avastin’s Breast Cancer Approval Followed CDER Rift On Efficacy

May 30 2011

Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

Nov 18 2011

FDA’s Guide For Selectively Collecting Safety Data

May 07 2012

ASCO Seeks More Aggressive Approach On Limiting Safety Data Collection

May 07 2012

Tykerb/Herceptin Combination Will Go Before FDA Advisory Panel

May 30 2012

FDA Will Revisit Appropriate Use Of PFS Endpoints At Advisory Committee

Sep 16 2009

Related Companies

GSK plc

Roche Holding AG

Genentech, Inc.

GSK plc

Additional Topics

United States Advisory Committees Drug Approval Standards Clinical Trials BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window